Approvals/TGA/YERVOY ipilimumab (rch) 200mg in 40mL (5mg/mL) concentrate solution for IV infusion vial

Approved

STANDARD

YERVOY ipilimumab (rch) 200mg in 40mL (5mg/mL) concentrate solution for IV infusion vial

Bristol-Myers Squibb Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: f9b1f658f8d01fd8
Product Name: YERVOY ipilimumab (rch) 200mg in 40mL (5mg/mL) concentrate solution for IV infusion vial
Artg Id: 174322
Artg Name: YERVOY ipilimumab (rch) 200mg in 40mL (5mg/mL) concentrate solution for IV infusion vial
Sponsor: Bristol-Myers Squibb Australia Pty Ltd
Company Detail Path: /organization/bristol-myers-squibb-australia-pty-ltd
Artg Date: 2011-07-04
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/2d6ccf0b75159c0a76df520ab879c578.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/3182b6de425ac8d57e180b5f6d4c40fb.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

May 31, 2025

Approval ID

f9b1f658f8d01fd8

Type

Standard